New Onset Behavioral Changes, Abnormal Movements and Seizures in a Two-and-Half Year-Old Girl: Pediatric Case of Anti-N-methyl-Daspartate receptor (NMDAR) encephalitis from Pakistan

Mohammad Raza, MBBS, FCPS, Rijaa Zaheer, MBBS*, Rafia Jabbar, MBBS

Consultant Pediatric Medicine, Karachi, Pakistan.

*Corresponding author

*Rijaa Zaheer, Consultant Pediatric Medicine, Karachi, Pakistan.

Abstract

Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis is now an increasingly recognized clinical entity among children, being identified as a predominant cause of encephalitis in cases which were previously labelled as idiopathic. There is paucity of literature reported on this variant of encephalitis in our country in   the pediatric age group. Hereby, we highlight a case of a two-and-half year-old girl from Karachi, Pakistan with anti-NMDAR encephalitis who presented with repeated seizures and decreased consciousness. Later on, she developed severe orofacial dyskinesias, choreoathetoid movements of the limbs and behavioral changes like agitation and aggression. This disease should be suspected in any child with unusual presentation of encephalitis to timely diagnose the disease and initiate immunotherapy to improve the outcome.

Keywords: Anti-NMDAR encephalitis, psychiatric-behavioral symptoms, intravenous immunoglobulins, rituximab.

Introduction

Anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis is a variant of autoimmune encephalitis, now being considered as second most common cause of pediatric encephalitis (1). It was first described in young women as a disorder associated with ovarian teratomas. Due to variable presentation, the diagnosis is difficult and often delayed (1)(2). The disease evolves in three clinical stages; a prodromal phase, an early phase manifested by seizures, behavioural, psychiatric disturbances; and a late stage characterized by hyperkinetic movements (2). In this disease antibodies target NR1 subunit of NMDA receptor, a neuronal cell surface protein involved in synaptic transmission and plasticity(3)(4). Diagnosis is confirmed by CSF anti-NMDAR antibodies, and antibody titter correlates with disease severity (4). Corticosteroids and intravenous immunoglobulin (IVIG) are considered first line therapies and early initiation of treatment improves outcome (1). We report a case of anti-NMDAR encephalitis in a toddler, marked by severe behavioural disturbances, choreoathetoid movements and seizures, who showed improvement in seizures and behaviour after IVIG therapy. Consent was taken prior to writing manuscript from the child’s parents.

Case Report

A two-and-a-half-year-old girl presented at the Indus Hospital & Health Network, Korangi Campus, Karachi in 2021 with complaints of altered behaviour, decreased consciousness and seizures for the last 3 days. Her illness started with fever 1 week back which persisted for a few days, and then subsided when she arrived to the hospital. She had had intermittent episodes of generalized tonic-clonic seizures at home and was persistently drowsy according to her parents. She was a healthy girl before this illness. There was no history of trauma, diarrhoea or viral symptoms preceding the illness. She was a developmentally appropriate child, with no past history of seizures. Her birth, vaccination and family history were unremarkable. On admission, her physical examination revealed an unoriented child with height at 75th centile, weight at 50th centile and front occipital circumference of 49 cm. Her pulse was 122beats per min, RR 30 breaths per min and BP 99/55 mmHg. Neurological examination showed GCS 9/15, hypotonia with normal reflexes and decreased power 3/5 in all four limbs. Her cranial nerves were intact but higher mental functions including memory, speech and cognition were lost. Rest of the systemic examination was unremarkable.

She was admitted initially in high dependency unit as a case of suspected meningoencephalitis, was given ceftriaxone and acyclovir empirically and managed for seizures with IV Levetiracetam. Neuroprotective measures (Head in midline with 30-degree elevation, normal oxygenation, ventilation, euglycemia, normothermia, normotensive, monitoring of vitals, perfusion was done and ensured for the signs of raised ICP, seizures and electrolyte imbalance) Her baseline labs including blood counts, renal & liver functions and serum electrolytes were all within normal limits. Her lumbar puncture was done and CSF showed a sugar of 65mg/dl, protein of 25mg/dl and cells 3.0/ul. HSV PCR came out to be negative. There was no response to acyclovir. Her seizures remained uncontrolled despite giving maximum dose of levetiracetam and topiramate and phenobarbitone had to be added to control the seizures. MRI brain with contrast was done which was unremarkable.

After a few days of admission, she developed involuntary movements of limbs and face, suggestive of choreoathetosis and orofacial dyskinesias, respectively. She also exhibited psychiatric-behavioural symptoms with prominent anxiety, agitation and aggression; had bouts of such episodes during which she shouted out loudly and pulled out her hair. These symptoms were progressive and frequent along with insomnia. She was put on clonazepam, haloperidol and clonidine to control these worsening symptoms. There were no signs of autonomic instability. She also had a few manic episodes in between with excessive laughter. There was regression in her gross and fine motor skills. She could not make social or eye contact and could not speak.  Her EEG was done which showed diffuse slow activity in the delta and theta range.

On the basis of these symptoms, a suspected diagnosis of autoimmune encephalitis was made, workup was sent and immunotherapy was started empirically. A repeat lumbar puncture was done to send samples for CSF anti-NMDA receptor antibodies and CSF oligoclonal bands. CSF again did not show pleocytosis or increased protein. Meanwhile, she was given IV methylprednisolone pulse therapy (30mg/kg) once a day for 5 days. There was no significant response to pulse therapy so, she was given intravenous immunoglobulins (IVIG) 1 gm/kg for 2 days. This resulted in improvement in some of her behavioural symptoms, insomnia and seizures, but her social, verbal, gross and fine motor skills did not improve. Her CSF anti NMDAR antibodies were reported positive (+++) and oligoclonal bands were present in CSF.  This confirmed our diagnosis of anti NMDAR encephalitis. She was worked up for underlying teratoma by ultrasound abdomen and pelvis, which was found to be normal. She was discharged to home on oral medications and called for follow-up in out-patient clinic. Her parents were counselled regarding the disease prognosis and slow recovery. The patient lost to follow in opd.

Figure 1: CT scan; Axial section of the lesion

Figure 2: CT scan; Coronal and 3D sections of the lesion

Figure 3: MRI image of the lesion across axial section

Figure 4: MRI image of the lesion across sagittal section

Figure 5: MRI image of the lesion across coronal section

Figure 6: Histopathology of the lesion

Figure 7: Per-operative photograph of patient

Figure 8: Post-operative photograph of patient

The CT scan (fig. 1, 2) showed a voluminous expansive process centred on the right mandibular horizontal ramus and angle, with a significant periosteal reaction in the form of a grass fire, suggesting in the first instance a sarcomatous origin. MRI (Fig. 3,4,5) also showed a voluminous right mandibular process with significant locoregional extension, muscle invasion and bilateral lymph node involvement, also suggesting a sarcomatous origin at first. A biopsy was performed, which showed a grade II, moderately differentiated mandibular chondrosarcoma (Fig. 6)

Our patient's treatment consisted of a right hemimandibulectomy with pelvectomy, combined with triangular lymph node dissection. The mandible was reconstructed with an angled maxiplate, and the floor of the mouth with a flap of the pectoralis major muscle (Fig. 7,8). Post-operative adjuvant radiotherapy was performed on the tumour site and lymph nodes.

Discussion

Anti-NMDAR encephalitis is rare under 3 years , with a wide variation in presentation, and most commonly presents with abnormal behaviour, movement disordersand seizures(5). It is a disabling but potentially treatable condition and is the most common autoimmune encephalitis(6). Limited cases of pediatric autoimmune encephalitis have been reported. In young children, abnormal movements and behavioural symptoms are more common like irritability, agitation, aggression and tantrums. Insomnia can also be a presenting symptom(7)(8). It mostly presents in childhood, 40% of all reported cases (9)and gender ratio in children under 10 years of age is nearly equal(2). Our case is about a female toddler, who presented with repeated seizures and decreased consciousness, and later on developed severe agitation, aggression, mania, insomnia and choreoathetosis.

In a series of 32 children and adolescents with anti-NMDAR encephalitis, 85% developed stereotyped movements and 45% developed orofacial dyskinesias (4). Our patient also had a severe form of movement disorder, evidenced by orofacial dyskinesias and choreoathetoid movements of the limbs.

Regarding investigations, CSF is usually abnormal showing lymphocytic pleocytosis (87%) and oligoclonal bands (60%) (1). MRI brain is abnormal in 35% children, showing non-specific cortical and subcortical T2 signal abnormalities. White matter abnormalities can also be present (1, 8). Our case was unusual in this regard that CSF analysis and MRI brain were unremarkable; but oligoclonal bands were present in CSF. As the disease severity corresponds to antibody titters(1), it  suits best in our patient  whose CSF antibody levels were severely elevated  and her clinical presentation was of severe category.

Treatment includes control of seizures, behaviour control, control of abnormal movement (10) with symptomatic treatment, definitive immunotherapy, and tumour surveillance (2). High-dose intravenous methylprednisolone, intravenous immunoglobulins, and plasmapheresis  are the first line immunotherapies and they are  found to be 90% effective, while on the other hand, it was found that patients may need second-line therapy with rituximab or cyclophosphamide(6)(2). We used high dose methylprednisolone and IVIG in our case, along with supportive treatment for movement disorder and seizures. There was improvement in behavioral symptoms and seizures after giving IVIG in our patient.

Conclusion

Anti-NMDAR encephalitis should be included in the differential diagnosis whenever there is an unusual presentation of encephalitis with abnormal movements, behavioral disturbances or psychiatric symptoms, so that timely specific treatment can be initiated to improve the outcome. There is a need to raise awareness about this disease entity in our country by reporting more cases of this disease due to variable presentation.

References

  1. Remy KE, Custer JW, Cappell J, Foster CB, Garber NA, Walker LK, et al. Pediatric anti-N-methyl-d-aspartate receptor encephalitis: a review with pooled analysis and critical care emphasis. Front Pediatr 2017;5:250.doi: 10.3389/fped.2017.00250.
  2. Dale RC, Gorman MP, Lim M. Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges. Curr Opin Neurol. 2017;30(3):334-44. doi: 1097/WCO.0000000000000443
  3. Consoli A, Ronen K, An-Gourfinkel I, Barbeau M, Marra D, Costedoat-Chalumeau N, et al. Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: case report. Child Adolesc Psychiatry Ment Health 2011;5(1):1-6.doi: 10.1186/1753-2000-5-15
  4. Baizabal‐Carvallo JF, Stocco A, Muscal E, Jankovic J. The spectrum of movement disorders in children with anti‐NMDA receptor encephalitis. Mov Disord 2013;28(4):543-547. DOI: 1002/mds.25354
  5. Ho AC-c, Chan SH-s, Chan E, Wong SS-n, Fung ST-h, Cherk SW-w, et al. Anti-N-methyl-d-aspartate receptor encephalitis in children: incidence and experience in Hong Kong. Brain Dev. 2018;40(6):473-479. doi: 1016/j.braindev.2018.02.005
  6. Rutatangwa A, Mittal N, Francisco C, Nash K, Waubant E. Autoimmune encephalitis in children: a case series at a tertiary care center. J Child Neurol. 2020;35(9):591-599. DOI: 1177/0883073820923834
  7. Goldberg TN, Cellucci MF. New onset insomnia in a pediatric patient: a case of anti-NMDA receptor encephalitis. Case Rep Pediatr. 2017;2017. doi: 1155/2017/4083785
  8. Cellucci T, Van Mater H, Graus F, Muscal E, Gallentine W, Klein-Gitelman MS, et al. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol Neuroimmunol Neuroinflamm. 2020;7(2). doi: 1212/NXI.0000000000000663
  9. Khundakji Y, Masri A, Khuri-Bulos N. Anti-NMDA receptor encephalitis in a toddler: A diagnostic challenge. Int J Pediatr Adolesc Med 2018;5(2):75-77. DOI: 1016/j.ijpam.2018.03.001
  10. Suthar R, Saini AG, Sankhyan N, Sahu JK, Singhi P. Childhood Anti-NMDA Receptor Encephalitis. Indian J Pediatr.. 2016;83(7):628-633. doi: 10.1007/s12098-015-1988-8.
TOP